{
    "root": "2f360fd4-b6b0-7540-e063-6394a90aa720",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ATROPINE SULFATE",
    "value": "20250228",
    "ingredients": [
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "SULFURIC ACID",
            "code": "O40UQP6WCF",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26836"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "ATROPINE SULFATE",
            "code": "03J5ZE7KA5",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_233047"
        }
    ],
    "indications": {
        "text": "atropine sulfate injection , usp , indicated temporary blockade severe life threatening muscarinic effects , e.g . , antisialagogue , antivagal agent , antidote organophosphorus muscarinic mushroom poisoning , treat bradyasystolic cardiac arrest .",
        "doid_entities": [
            {
                "text": "cardiac arrest (DOID:0060319)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060319"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "intravenous ( 2.1 ) titrate according heart rate , pr interval , blood pressure symptoms ( 2.1 ) adult antisialagogue antivagal effects : initial single dose 0.5 1 mg ( 2.2 ) antidote organophosphorus muscarinic mushroom poisoning : initial single dose 2 3 mg , repeated every 20-30 minutes ( 2.2 ) bradyasystolic cardiac arrest : 1 mg dose , repeated every 3-5 minutes asystole persists ( 2.2 ) patients coronary artery disease : limit total dose 0.03 0.04 mg/kg ( 2.4 )",
        "doid_entities": [
            {
                "text": "cardiac arrest (DOID:0060319)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060319"
            },
            {
                "text": "coronary artery disease (DOID:3393)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3393"
            },
            {
                "text": "artery disease (DOID:0050828)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050828"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "atropine sulfate injection , usp 0.4 1 mg/ml supplied 1 ml , single-dose glass vials follows : table 2 : supplied concentration ( mg/ml ) package size ndc # 0.4 mg/ml 1 vial 16729-525-63 10 vials 16729-525-03 25 vials 16729-525-08 1 mg/ml 1 vial 16729-526-63 10 vials 16729-526-03 25 vials 16729-526-08 store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) . [ usp controlled room temperature . ] manufactured : accord healthcare , inc. , 8041 arco corporate drive , suite 200 , raleigh , nc 27617 , usa . manufactured : intas pharmaceuticals limited , ahmedabad-380 054 , india . 10 4020 2 6026794 november 2023",
    "adverseReactions": "none .",
    "indications_original": "Atropine Sulfate Injection, USP, is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest.",
    "contraindications_original": "For intravenous administration ( 2.1 ) Titrate according to heart rate, PR interval, blood pressure and symptoms\u00a0( 2.1 ) Adult dosage Antisialagogue or for antivagal effects: Initial single dose of 0.5 to 1\u00a0mg ( 2.2 ) Antidote for organophosphorus or muscarinic mushroom poisoning: Initial single dose of 2 to 3 mg, repeated every 20-30 minutes ( 2.2 ) Bradyasystolic cardiac arrest: 1 mg dose, repeated every 3-5 minutes if asystole persists ( 2.2 ) Patients with Coronary Artery Disease: Limit the total dose to 0.03 to 0.04 mg/kg ( 2.4 )",
    "warningsAndPrecautions_original": "Atropine Sulfate Injection, USP 0.4 and 1 mg/mL are supplied in 1 mL, single-dose glass vials as follows:\n                  Table 2: How Supplied\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Concentration (mg/mL)\n                              \n                           \n                           \n                              \n                                 Package Size\n                              \n                           \n                           \n                              \n                                 NDC #\n                              \n                           \n                        \n                        \n                           \n                              0.4 mg/mL\n                           \n                           \n                              1 Vial\n                           \n                           \n                              16729-525-63\n                           \n                        \n                        \n                           \n                              10 Vials\n                           \n                           \n                              16729-525-03\n                           \n                        \n                        \n                           \n                              25 Vials\n                           \n                           \n                              16729-525-08\n                           \n                        \n                        \n                           \n                              1 mg/mL\n                           \n                           \n                              1 Vial\n                           \n                           \n                              16729-526-63\n                           \n                        \n                        \n                           \n                              10 Vials\n                           \n                           \n                              16729-526-03\n                           \n                        \n                        \n                           \n                              25 Vials\n                           \n                           \n                              16729-526-08\n                           \n                        \n                     \n                  \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F). [See USP Controlled Room Temperature.]\n                  \n                     Manufactured For:\n                     \n                       Accord Healthcare, Inc., \n  \n                       8041 Arco Corporate Drive, \n  \n                       Suite 200, \n  \n                       Raleigh, NC 27617, \n  \n                       USA.\n\n \n                  \n                     Manufactured By:\n                     \n                       Intas Pharmaceuticals Limited, \n  \n                       Ahmedabad-380 054, India.\n\n \n                  \n                  10 4020 2 6026794\n                  \n                  November 2023",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "ATROPINE SULFATE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_233047"
        }
    ]
}